BR Nihalani and DG Hunter

Children's Hospital Boston, Harvard Medical School, Boston, MA, USA
E-mail: david.hunter@childrens.harvard.edu.

Eye (2012) **26,** 1025–1026; doi:10.1038/eye.2012.65; published online 13 April 2012

Sir,

First postoperative day intraocular pressure rise in resident-performed cataract surgery

We read the article by Kim *et al*[1] with interest and would like to highlight some concerns regarding their data and conclusions.

The title and purpose of the study seems to indicate outcomes for a particular surgeon group (residents in training); however, the conclusions are not supported by the data. Amongst 1582 procedures, after excluding surgery complicated with vitreous loss, 305/1582 procedures were performed by attending surgeons and further excluded from analysis. The outcomes of these 305 surgeries is reported in the discussion as having an incidence of first postoperative day intraocular pressure (IOP) elevation no higher than the trainee-performed surgery ($P = 0.94$, χ^2-test). The authors have surprisingly chosen to present the study as a consecutive case series instead of a more useful comparative study.

There is a discrepancy in the use of ophthalmic viscosurgical device (OVD). The methodology states use of two agents: Healon (1% sodium hyaluronate) initially in 2001 to 2005 and thereafter Duovisc, which is composed of two OVDs, the cohesive Provisc (1% sodium hyaluronate) and dispersive Viscoat (sodium chondroitin sulphate 4%–sodium hyaluronate 4%). However, in Table 2 the OVD reported as used is Healon GV, a hyaluronic acid product with a 10-times higher viscosity than Healon, preferred in complicated procedures (vitreous pressure, flat anterior chamber, so on) and thus probably chosen for resident surgery. The effect of OVDs with higher molecular weight and viscosity on postoperative IOP is well documented.[2,3] This may well explain the reason for this case series having a higher postoperative IOP 24 h after cataract surgery (22%, >23 mm Hg and 14.9%, >26 mm Hg) than the previously reported values of 2.57%[4] and 11.8%,[5] respectively.

The effect of trainee surgeons on early IOP rise after cataract surgery can be a consequence of relatively more manipulations, residual OVD, and subsequent increased inflammation. This hypothesis maybe better supported by data on central corneal thickness, aqueous flare, surgery duration, phacoemulsification power etc as well as a comparative case–control study design.

Conflict of interest

The authors declare no conflict of interest.

References

1 Kim JY, Jo M-W, Brauner SC, Ferrufino-Ponce Z, Ali R, Cremers SL *et al*. Increased intraocular pressure on the first postoperative day following resident-performed cataract surgery. *Eye* 2011; **25**: 929–936.
2 Arshinoff SA, Albiani DA, Taylor-Laporte J. Intraocular pressure after bilateral cataract surgery using Healon, Healon5, and Healon GV. *J Cataract Refract Surg* 2002; **28**: 617–625.
3 Thirumalai B, Blamires TL, Brooker L, Deeks J. Heavier molecular weight ocular viscoelastic devices and timing of post-operative review following cataract surgery. *BMC Ophthalmol* 2007; **7**: 2.
4 Jaycock P, Johnston RL, Taylor H, Adams M, Tole DM, Galloway P *et al*. The Cataract National Dataset electronic multi-centre audit of 55,567 operations: updating benchmark standards of care in the United Kingdom and internationally. *Eye* 2009; **23**: 38–49.
5 Browning AC, Alwitry A, Hamilton R, Rotchford A, Bhan A, Amoaku WM. Role of intraocular pressure measurement on the day of phacoemulsification cataract surgery. *J Cataract Refract Surg* 2002; **28**: 1601–1606.

R Chaudhary and A Kadyan

Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK
E-mail: anjukadyan@btinternet.com

Eye (2012) **26,** 1026; doi:10.1038/eye.2012.70; published online 27 April 2012

Sir,

Comment to 'First postoperative day intraocular pressure rise in resident-performed cataract surgery'

We appreciate Drs Chaudhary and Kadyan's interest[1] in our article regarding the elevated intraocular pressure (IOP) on the first postoperative day following resident-performed cataract surgery.[2]

Our study was a comparative study and not a consecutive case series. Although all consecutive surgeries were considered, only 1111 cataract surgeries performed by residents between 1 July 2001 and 30 June 2006 were included in this study owing to the exclusions of some cases for the reasons listed.[2]

We acknowledge that the types of ophthalmic viscosurgical device (OVD) were not evenly distributed during our study period. As we commented in the Methods, sodium hyaluronate (Healon; Abbott Medical Optics Inc., Santa Ana, CA, USA) was used for all procedures from July 2001 to November 2005, and combined chondroitin sulfate and sodium hyaluronate (Duovisc; Alcon Laboratories Inc., Fort Worth, TX, USA) were used for all procedures after this time.[2] Owing to the retrospective nature of the study, the type of viscoelastic could not be controlled.

The 'GV' in 'Healon GV' was an error in Tables 2 and 3. It should read 'Healon' instead. We are grateful to Drs Chaudhary and Kadyan for alerting us to the error.